Join the Oncology Voice Network. Join for Free
Season 1, Episode 13: Leadership Through Vulnerability with Gwen Binder

Season 1, Episode 13: Leadership Through Vulnerability with Gwen Binder


Share This Article


In today's episode our host Michael Pietrack sits down with Gwendolyn Binder, President of Science and Technologies at Cabaletta Bio, shares her insights on leadership. She discusses how she became an accidental leader and the importance of focusing on advancing the ball for patients rather than personal recognition. Binder emphasizes the need for leaders to embrace uncertainty and have an entrepreneurial attitude. She also highlights the importance of unleashing the potential of others and aligning a unified vision. Binder discusses the role of culture in leadership and the need for leaders to be vulnerable and create a teamwork culture. She provides tips for hiring and emphasizes the importance of no-regret hires. "Instead of trying to think how can I climb the ladder, it's how can I be of most use continually?" Binder also addresses the challenges and advice for female leaders. Tune in to hear it all!

Takeaways

🏀Focus on advancing the ball for patients rather than personal recognition.

🤗Embrace uncertainty and have an entrepreneurial attitude.

💹Unleash the potential of others and align a unified vision.

➡⬅Create a teamwork culture by being vulnerable and open.

☑Make no-regret hires by assessing cultural fit and soft skills.

🚺Acknowledge and address the challenges faced by female leaders. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN